How unstructured EMR data helps pharma find patients
As therapies have become more complex, pharma companies are now challenged to achieve precision targeting within a much tighter timeframe. While claims data is readily available, one of its key limitations is the lack of timeliness. Many manufacturers now rely on specialized lab data—from imaging results to genetic testing and genomics—to identify eligible patients and […]
Connecting the dots with NorstellaLinQ
Norstella’s VP of thought leadership, Daniel Chancellor, was invited to share his perspectives on the proliferation of data with the leading publication The Medicine Maker. The timing was perfect, coming shortly after we launched NorstellaLinQ, the biopharma industry’s first fully integrated data asset. The article explores various themes such as abundance, the importance of data […]
Spotlight on South Korea: Innovation, clinical trials, and market trends shaping 2025
In a series exploring trends across the APAC region, Norstella’s subject matter experts from key biopharma hubs delve into this year’s standout developments and share their outlook for 2025. South Korea has firmly established itself as a global biopharma innovation hub, ranking third worldwide in new drug discoveries. According to Citeline’s Pharmaprojects database, South Korean […]